DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Orteronel is an investigational drug.
There have been 17 clinical trials for Orteronel. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and University of Wisconsin, Madison.
There are five US patents protecting this investigational drug and forty-seven international patents.
Recent Clinical Trials for Orteronel
|AR-inhibitor Bicalutamide in Treating Patients With TNBC||Jiangsu Province Hospital of Traditional Chinese Medicine||Phase 2|
|AR-inhibitor Bicalutamide in Treating Patients With TNBC||Nanning Second People's Hospital||Phase 2|
|AR-inhibitor Bicalutamide in Treating Patients With TNBC||The First People's Hospital of Lianyungang||Phase 2|
Top disease conditions for Orteronel
Top clinical trial sponsors for Orteronel
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Orteronel||See Pricing||Modulation of androgen receptor expression||ISIS Pharmaceuticals Inc. (Carlsbad, CA)||See Pricing|
|Orteronel||See Pricing||Androgen receptor down-regulating agents and uses thereof||University of Maryland, Baltimore (Baltimore, MD)||See Pricing|
|Orteronel||See Pricing||Modulation of androgen receptor expression||Ionis Pharmaceuticals, Inc. (Carlsbad, CA)||See Pricing|
|Orteronel||See Pricing||Inhibitors of CYP17A1||UNIVERSITY OF KANSAS (Lawrence, KS)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|